Itraconazole: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| (6 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
== Background == |
|||
* Azole antifungal |
* Azole antifungal |
||
* Indications include {{#ask: [[Is treated by::itraconazole]]}} |
* Indications include {{#ask: [[Is treated by::itraconazole]]}} |
||
=== Pharmacokinetics === |
|||
== Therapeutic Drug Monitoring == |
|||
* Blood concentrations are about 30% higher with oral solution compared to oral capsules |
|||
* Wide intersubject variability in levels |
|||
* Serum half-life is long |
|||
* Metabolized by [[Metabolized by::CYP3A4]] and inhibits [[Inhibits::CYP3A4]] |
|||
* Excreted in urine and feces |
|||
=== Breakpoints === |
|||
{| class="wikitable" |
|||
! rowspan="2" |Species |
|||
! rowspan="2" |ECOFF (mg/L) |
|||
! colspan="4" |Breakpoints (μg/mL) |
|||
! colspan="4" |Breakpoints (mm) |
|||
|- |
|||
! S |
|||
! I |
|||
!SDD |
|||
!R |
|||
!S |
|||
!I |
|||
! SDD |
|||
! R |
|||
|- |
|||
| [[Candida albicans]] |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Candida glabrata]] |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Candida krusei]] |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Candida parapsilosis]] |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Candida tropicalis]] |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Cryptococcus neoformans]] |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Cryptococcus gattii]] |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Aspergillus flavus]] |
|||
|1 |
|||
|≤1 |
|||
| colspan="2" rowspan="5" | |
|||
|>1 |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Aspergillus fumigatus]] |
|||
| 1 |
|||
|≤1 |
|||
|>1 |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Aspergillus nidulans]] |
|||
|1 |
|||
|≤1 |
|||
|>1 |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Aspergillus niger]] |
|||
|4 |
|||
|— |
|||
|— |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Aspergillus terreus]] |
|||
|0.5 |
|||
|≤1 |
|||
|>1 |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|} |
|||
== Dosing == |
|||
* Preference for oral solution rather than capsules in severe infections (see PK section above) |
|||
* Can consider initial loading doses with IV or p.o |
|||
* Typical dose: 200 mg p.o. twice daily |
|||
* May be used once daily for the treatment of some [[Candida|candidal]] or [[dermatophytes|dermatophytic]] infections |
|||
== Safety == |
|||
=== Therapeutic Drug Monitoring === |
|||
* Recommended in more serious or severe infections |
|||
* Should be measured 5 to 7 days after starting or changing the dose, or when interacting medications are changed |
* Should be measured 5 to 7 days after starting or changing the dose, or when interacting medications are changed |
||
** Can likely be collected at any time after steady-state is reached, due to long halflife |
|||
* Target in prophylaxis is a trough ot 0.5 mg/L |
|||
* Target in |
* Target in prophylaxis is a trough level of 0.5 µg/mL |
||
* Target in treatment is a trough level greater than 0.5 µg/mL, or greater than 0.5 to 1 µg/mL for [[blastomycosis]] |
|||
* Toxicity likely increased at trough levels greated than 10 µg/mL |
|||
=== Adverse Drug Reactions === |
|||
* [[Adverse drug reaction::Headache]] |
|||
* [[Adverse drug reaction::Relative adrenal insufficiency]] |
|||
* [[Adverse drug reaction::Hepatotoxicity]] |
|||
* [[Adverse drug reaction::QTc prolongation]] |
|||
== Further Reading == |
|||
* Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. ''J Antimicrob Chemother.'' 2014;69(5):1162-1176. doi: [https://doi.org/10.1093/jac/dkt508 10.1093/jac/dkt508] |
|||
== Adverse Effects == |
|||
* [[Has adverse drug reaction::Headache]] |
|||
* [[Has adverse drug reaction::Relative adrenal insufficiency]] |
|||
* [[Has adverse drug reaction::Hepatotoxicity]] |
|||
* [[Has adverse drug reaction::QTc prolongation]] |
|||
[[Category: |
[[Category:Triazoles]] |
||
Latest revision as of 13:03, 22 October 2024
Background
- Azole antifungal
- Indications include Alternaria, Blastomyces dermatitidis, Chromoblastomycosis, Coccidioides immitis, Cryptococcus, Entomophthoromycotina, Exophiala, Exserohilum, Fonsecaea, Histoplasma capsulatum, Mycetoma, Paracoccidioides brasiliensis, Sappinia diploidea, Sporothrix schenckii
Pharmacokinetics
- Blood concentrations are about 30% higher with oral solution compared to oral capsules
- Wide intersubject variability in levels
- Serum half-life is long
- Metabolized by CYP3A4 and inhibits CYP3A4
- Excreted in urine and feces
Breakpoints
| Species | ECOFF (mg/L) | Breakpoints (μg/mL) | Breakpoints (mm) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| S | I | SDD | R | S | I | SDD | R | ||
| Candida albicans | |||||||||
| Candida glabrata | |||||||||
| Candida krusei | |||||||||
| Candida parapsilosis | |||||||||
| Candida tropicalis | |||||||||
| Cryptococcus neoformans | |||||||||
| Cryptococcus gattii | |||||||||
| Aspergillus flavus | 1 | ≤1 | >1 | ||||||
| Aspergillus fumigatus | 1 | ≤1 | >1 | ||||||
| Aspergillus nidulans | 1 | ≤1 | >1 | ||||||
| Aspergillus niger | 4 | — | — | ||||||
| Aspergillus terreus | 0.5 | ≤1 | >1 | ||||||
Dosing
- Preference for oral solution rather than capsules in severe infections (see PK section above)
- Can consider initial loading doses with IV or p.o
- Typical dose: 200 mg p.o. twice daily
- May be used once daily for the treatment of some candidal or dermatophytic infections
Safety
Therapeutic Drug Monitoring
- Recommended in more serious or severe infections
- Should be measured 5 to 7 days after starting or changing the dose, or when interacting medications are changed
- Can likely be collected at any time after steady-state is reached, due to long halflife
- Target in prophylaxis is a trough level of 0.5 µg/mL
- Target in treatment is a trough level greater than 0.5 µg/mL, or greater than 0.5 to 1 µg/mL for blastomycosis
- Toxicity likely increased at trough levels greated than 10 µg/mL
Adverse Drug Reactions
Further Reading
- Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69(5):1162-1176. doi: 10.1093/jac/dkt508
